Protein Glycosylation in Infectious Disease Pathobiology and Treatment

Overview

Journal Cent Eur J Biol

Specialty Biology

Date 2020 Mar 28

PMID 32215117

Citations 7

Authors

David J Vigerust

Affiliations

Soon will be listed here.

Abstract

A host of bacteria and viruses are dependent on O-linked and N-linked glycosylation to perform vital biological functions. Pathogens often have integral proteins that participate in host-cell interactions such as receptor binding and fusion with host membrane. Fusion proteins from a broad range of disparate viruses, such as paramyxovirus, HIV, ebola, and the influenza viruses share a variety of common features that are augmented by glycosylation. Each of these viruses contain multiple glycosylation sites that must be processed and modified by the host post-translational machinery to be fusogenically active. In most viruses, glycosylation plays a role in biogenesis, stability, antigenicity and infectivity. In bacteria, glycosylation events play an important role in the formation of flagellin and pili and are vitally important to adherence, attachment, infectivity and immune evasion. With the importance of glycosylation to pathogen survival, it is clear that a better understanding of the processes is needed to understand the pathogen requirement for glycosylation and to capitalize on this requirement for the development of novel therapeutics.

Citing Articles

Differential substrate preferences IN ACTINOBACTERIAL protein O-MANNOSYLTRANSFERASES and alteration of protein-O-MANNOSYLATION by choice of secretion pathway.

Saxena H, Patel R, Kelly J, Wakarchuk W Glycobiology. 2024; 35(1).

PMID: 39673494 PMC: 11727336. DOI: 10.1093/glycob/cwae095.

Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects.

Kobeissy F, Goli M, Yadikar H, Shakkour Z, Kurup M, Haidar M Front Neurol. 2023; 14:1288740.

PMID: 38073638 PMC: 10703396. DOI: 10.3389/fneur.2023.1288740.

First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients.

Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B BMC Gastroenterol. 2021; 21(1):443.

PMID: 34819046 PMC: 8612383. DOI: 10.1186/s12876-021-01988-y.

The glycosylation in SARS-CoV-2 and its receptor ACE2.

Gong Y, Qin S, Dai L, Tian Z Signal Transduct Target Ther. 2021; 6(1):396.

PMID: 34782609 PMC: 8591162. DOI: 10.1038/s41392-021-00809-8.

Functionalized High Mannose-Specific Lectins for the Discovery of Type I Mannosidase Inhibitors.

Kurhade S, Weiner J, Gao F, Farrell M Angew Chem Int Ed Engl. 2021; 60(22):12313-12318.

PMID: 33728787 PMC: 8131250. DOI: 10.1002/anie.202101249.

References

Bunnik E, Euler Z, Welkers M, Boeser-Nunnink B, Grijsen M, Prins J . Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med. 2010; 16(9):995-7. DOI: 10.1038/nm.2203. View

Schirm M, Soo E, Aubry A, Austin J, Thibault P, Logan S . Structural, genetic and functional characterization of the flagellin glycosylation process in Helicobacter pylori. Mol Microbiol. 2003; 48(6):1579-92. DOI: 10.1046/j.1365-2958.2003.03527.x. View

Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, Bovin N . Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology. 2003; 307(1):90-7. DOI: 10.1016/s0042-6822(02)00064-8. View

Calarese D, Lee H, Huang C, Best M, Astronomo R, Stanfield R . Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A. 2005; 102(38):13372-7. PMC: 1224641. DOI: 10.1073/pnas.0505763102. View

Vigerust D, Ulett K, Boyd K, Madsen J, Hawgood S, McCullers J . N-linked glycosylation attenuates H3N2 influenza viruses. J Virol. 2007; 81(16):8593-600. PMC: 1951338. DOI: 10.1128/JVI.00769-07. View

Bertaux C, Daelemans D, Meertens L, Cormier E, Reinus J, Peumans W . Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology. 2007; 366(1):40-50. DOI: 10.1016/j.virol.2007.04.008. View

Balzarini J . Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?. Antivir Chem Chemother. 2007; 18(1):1-11. DOI: 10.1177/095632020701800101. View

Poumbourios P, Maerz A, Drummer H . Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41. J Biol Chem. 2003; 278(43):42149-60. DOI: 10.1074/jbc.M305223200. View

Cambi A, Figdor C . Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol. 2003; 15(5):539-46. DOI: 10.1016/j.ceb.2003.08.004. View

10.

Londrigan S, Turville S, Tate M, Deng Y, Brooks A, Reading P . N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN. J Virol. 2010; 85(6):2990-3000. PMC: 3067946. DOI: 10.1128/JVI.01705-10. View

11.

Naarding M, Baan E, Pollakis G, Paxton W . Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007; 4:6. PMC: 1796897. DOI: 10.1186/1742-4690-4-6. View

12.

Boelaert J, Sperber K, Piette J . Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res Hum Retroviruses. 1999; 15(14):1241-7. DOI: 10.1089/088922299310133. View

13.

Calarese D, Scanlan C, Zwick M, Deechongkit S, Mimura Y, Kunert R . Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003; 300(5628):2065-71. DOI: 10.1126/science.1083182. View

14.

Witze E, Old W, Resing K, Ahn N . Mapping protein post-translational modifications with mass spectrometry. Nat Methods. 2007; 4(10):798-806. DOI: 10.1038/nmeth1100. View

15.

Witvrouw M, Fikkert V, Hantson A, Pannecouque C, OKeefe B, McMahon J . Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol. 2005; 79(12):7777-84. PMC: 1143621. DOI: 10.1128/JVI.79.12.7777-7784.2005. View

16.

Deshpande K, Fried V, Ando M, Webster R . Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc Natl Acad Sci U S A. 1987; 84(1):36-40. PMC: 304136. DOI: 10.1073/pnas.84.1.36. View

17.

Doores K, Bonomelli C, Harvey D, Vasiljevic S, Dwek R, Burton D . Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A. 2010; 107(31):13800-5. PMC: 2922250. DOI: 10.1073/pnas.1006498107. View

18.

Bossart K, Crameri G, Dimitrov A, Mungall B, Feng Y, Patch J . Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol. 2005; 79(11):6690-702. PMC: 1112112. DOI: 10.1128/JVI.79.11.6690-6702.2005. View

19.

Davis C, Mattei L, Nguyen H, Ansarah-Sobrinho C, Doms R, Pierson T . The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem. 2006; 281(48):37183-94. DOI: 10.1074/jbc.M605429200. View

20.

Vigerust D, McCullers J . Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses. 2009; 1(5-6):189-92. PMC: 4941887. DOI: 10.1111/j.1750-2659.2007.00027.x. View